Antibiotics

Eurofins Genomics AgriGenomics Europe and Gencove announce collaboration to offer complete solution for low-pass whole genome sequencing

Retrieved on: 
Tuesday, April 9, 2024
Agriculture, Partnership, DNA, SNP, Doctor of Philosophy, Genomics, Aquaculture, Antibiotics

New York, USA and Galten, Denmark, April 09, 2024 (GLOBE NEWSWIRE) -- Eurofins Genomics AgriGenomics Europe, an internationally leading provider of DNA sequencing and genotyping services and Gencove, a pioneer of low-pass whole genome sequencing (lpWGS) imputation and analysis, today announced a partnership to offer a complete solution for lpWGS in Europe, delivering high-throughput and cost-effective sequencing.

Key Points: 
  • New York, USA and Galten, Denmark, April 09, 2024 (GLOBE NEWSWIRE) -- Eurofins Genomics AgriGenomics Europe, an internationally leading provider of DNA sequencing and genotyping services and Gencove, a pioneer of low-pass whole genome sequencing (lpWGS) imputation and analysis, today announced a partnership to offer a complete solution for lpWGS in Europe, delivering high-throughput and cost-effective sequencing.
  • The partnership will combine Gencove’s platform for data analytics and management with Eurofins Genomics AgriGenomics Europe’s capabilities running low-pass whole genomics sequencing to usher in a new era in genotyping.
  • The collaboration leverages both companies' strengths in sequencing to accelerate advancements in genotyping benefiting plant breeders, livestock selectors, aquaculture, and companion animal sectors.
  • In making large-scale genomic information more accessible and actionable, Gencove and Eurofins Genomics AgriGenomics Europe are setting new benchmarks for what is possible in agriculture.

S2 Genomics Announces Groundbreaking Single Cell FFPE Sample Prep Isolation Product

Retrieved on: 
Tuesday, April 9, 2024
Chemicals, Plastics, Electronic Design Automation, Manufacturing, Technology, Stem Cells, Pharmaceutical, Oncology, Medical Devices, Genetics, Clinical Trials, Other Manufacturing, Other Technology, Biotechnology, Science, Research, Health, Genomics, Tissue, RNA, The central science, Antibiotics

S2 Genomics, a pioneer in tissue sample preparation systems, today announced the launch of its latest product, the Singulator™ 200+ System, an automated sample prep isolation system for single cell formalin-fixed, paraffin-embedded (FFPE) tissues.

Key Points: 
  • S2 Genomics, a pioneer in tissue sample preparation systems, today announced the launch of its latest product, the Singulator™ 200+ System, an automated sample prep isolation system for single cell formalin-fixed, paraffin-embedded (FFPE) tissues.
  • The new FFPE sample prep isolation system is designed to isolate nuclei from FFPE tissue slices, enabling single-nucleus RNA sequencing (snRNA-Seq) for FFPE samples.
  • Jonathan Schimmel, President and CEO of S2 Genomics, expressed his enthusiasm for the new product: “The FFPE sample prep isolation system is a testament to our commitment to continuing innovation and excellence in the field of single cell genomics.
  • For more information about the FFPE sample prep isolation system and other S2 Genomics products, please visit us at s2genomics.com or connect with us on LinkedIn or Twitter .

Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio

Retrieved on: 
Friday, March 22, 2024
ASX, RCE, Canada Revenue Agency, AMR, Science, IP, Infection, Antibiotics

SYDNEY, Australia, March 22, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it has been issued a trademark registration for RECCE® from the Canadian Intellectual Property Office, strengthening its global intellectual property (IP) portfolio.

Key Points: 
  • SYDNEY, Australia, March 22, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it has been issued a trademark registration for RECCE® from the Canadian Intellectual Property Office, strengthening its global intellectual property (IP) portfolio.
  • 1289603 formally assigns RECCE® the Canada Trademark No.
  • “We are pleased to receive this newly registered trademark in Canada, building upon those already registered in the world’s largest pharmaceutical markets,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • The Canada Revenue Agency administers the program, aiming to incentivize businesses to conduct R&D in Canada, encouraging innovation and technological advancements.

Inocras Inc. Unveils Rebranding of Genome Insight

Retrieved on: 
Monday, March 18, 2024
Technology, Neurology, Genetics, Biotechnology, Other Health, Health, Data Management, Artificial Intelligence, Oncology, Disease, Patient, Research, Cancer, AI, CAP, CLIA, Whole genome sequencing, Nursing care plan, Antibiotics

Inocras, formerly known as Genome Insight, announced today its rebranding initiative to reflect its commitment to innovation and user-centric healthcare solutions.

Key Points: 
  • Inocras, formerly known as Genome Insight, announced today its rebranding initiative to reflect its commitment to innovation and user-centric healthcare solutions.
  • The AI-driven whole genome platform company, specialized in whole genome sequencing and analytics for cancer and rare diseases, has embarked on its rebranding to reinforce its dedication to shaping an "innovative tomorrow".
  • The rebranding accentuates its focus on "user-centric approaches" for patients, providers, and researchers, surpassing the provision of sequencing and analytics services.
  • Inocras Inc. (formerly Genome Insight Inc.) is a pioneering provider of whole genome sequencing and analytics services for cancer and rare diseases.

BioSkryb Launches New Whole Genome and Transcriptome Core Kits to Accelerate Single-Cell Multiomics

Retrieved on: 
Wednesday, March 13, 2024
Health Technology, Other Health, Technology, Oncology, General Health, Medical Devices, Neurology, Other Technology, Cardiology, Science, Biotechnology, Software, Other Science, Health, Research, PTA, Genome, Gene expression, Transcriptome, DNA, RNA, Figure skating jumps, Marketing, Workflow, Data, Genomics, SVS, WGA, Antibiotics

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.

Key Points: 
  • BioSkryb Genomics , a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.
  • As part of these new kit configurations, total workflow time has been reduced to under eight hours for both products.
  • “These new core kits provide researchers with an optimized and validated workflow that delivers industry-leading single-cell multiomic performance,” said Suresh Pisharody, CEO, BioSkryb.
  • The ResolveOME Whole Genome and Transcriptome Single-Cell Core Kit leverages its PTA-based WGA technology to couple each single cell’s whole genome with its full-length whole transcriptome.

Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay

Retrieved on: 
Tuesday, April 2, 2024
Diagnosis, WGS, Disease, FACMG, Broad Institute, Genetic testing, Fragile X syndrome, Massachusetts General Hospital, MIT, Harvard University, CMA, Patient, Medical genetics, Research, Mortality, Laboratory, DGX, Senior, Genome, American College, Saliva, Intellectual disability, Hospital, Whole genome sequencing, ACMG, Blood, Quest Diagnostics, Antibiotics

SECAUCUS, N.J., April 2, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Broad Clinical Labs, the world expert in whole genome sequencing (WGS), today announced a research collaboration designed to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.

Key Points: 
  • "We are delighted to bring the experience and expertise of Broad Clinical Labs to this innovative collaboration with Quest.
  • "This type of collaboration between commercial laboratories and research institutions is vital to advance the field of genetic testing and increase utility and economic value."
  • While the ACMG recommends WGS for first-line genetic testing for intellectual disability and developmental delay, some providers continue to follow prior guidelines that recommend chromosomal microarray (CMA) as a first-line test.
  • Broad Clinical Labs is a leader in human whole genome sequencing, having sequenced over 600,000 genomes in service of its mission to accelerate the understanding and diagnosis of human disease.

Second Opinion Expert Announces Strategic Relationship With Genome International

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Genomics, SOE, Pharmacogenomics, Genome, Patient, Clinical decision support system, Research, Hospital, Laboratory, Whole genome sequencing, Medicine, CDSS, Therapy, Physician, Antibiotics

LOS ANGELES, April 1, 2024 /PRNewswire/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that it has entered into a strategic relationship with Genome International to provide rapid Whole Genome Interpretation (WGI™) delivered by Genome Explorer®, a comprehensive Clinical Decision Support System that brings genomic information to the point of care.

Key Points: 
  • We are proud to be part of Genome International's revolutionary effort to put the power of the genome in the hands of healthcare practitioners worldwide.
  • SOE will assist Genome International with business development and strategy, leveraging SOE's relationships and expertise.
  • Genome Explorer® provides a single unified platform for whole genome variant interpretation with high accuracy and success across diseases.
  • "We are proud to be part of Genome International's revolutionary effort to put the power of the genome in the hands of healthcare practitioners worldwide."

CosmosID Announces Collaboration with Resilient Biotics for Advanced Microbiome Exploration of the Respiratory Tract

Retrieved on: 
Thursday, March 21, 2024
Therapy, Research, Antibiotics

DURHAM, N.C., March 21, 2024 /PRNewswire/ -- CosmosID, a renowned microbiome analytics company, is thrilled to announce a groundbreaking collaboration with Resilient Biotics, a leading microbiome platform company with a pipeline of products for maintaining respiratory tract health.

Key Points: 
  • DURHAM, N.C., March 21, 2024 /PRNewswire/ -- CosmosID, a renowned microbiome analytics company, is thrilled to announce a groundbreaking collaboration with Resilient Biotics, a leading microbiome platform company with a pipeline of products for maintaining respiratory tract health.
  • "We are excited to collaborate with CosmosID, a leader in the genomic sequencing space," said Chris Belnap, CEO of Resilient Biotics.
  • "We are honored to join forces with Resilient Biotics, a trailblazer in microbiome research," said Manoj Dadlani, president of CosmosID.
  • "Our collaboration aims to deepen our understanding of the respiratory tract's microbiome, which could redefine the future of respiratory health management.

Clinical Microbiomics adds World-Leading Expertise in Long-Read DNA & RNA Sequencing Technologies with Acquisition of DNASense ApS

Retrieved on: 
Friday, March 1, 2024
Acquisition, Soil, QMS, Animal, CCO, Global health, Metabolomics, RNA, Human, Environment, Quality management system, CSO, Agriculture, Laboratory, Research, DNA, Water, Partnership, Antibiotics

The acquisition expands Clinical Microbiomics' expertise and offering for new segments such as agriculture, industrial, and environmental ecosystems, and it adds cutting-edge long- read DNA- and RNA sequencing technologies to the extensive portfolio of multi-omics technologies for the microbiome field.

Key Points: 
  • The acquisition expands Clinical Microbiomics' expertise and offering for new segments such as agriculture, industrial, and environmental ecosystems, and it adds cutting-edge long- read DNA- and RNA sequencing technologies to the extensive portfolio of multi-omics technologies for the microbiome field.
  • H. Bjørn Nielsen, CSO of Clinical Microbiomics, "DNASense is a first mover in applying long-read technology broadly across microbiome research and industrial applications.
  • Mads Søndergaard, CEO of DNASense, comments on the synergies: "Joining Clinical Microbiomics is a pivotal moment for DNASense.
  • The DNASense acquisition facilitates expansion into new applications of microbiome science to better understand diverse biological systems and ecological dynamics.

EVŌQ Nano Announces That Its Antimicrobial Medical Device Platform Demonstrates Success Against the Leading Cause of Healthcare-Associated Infections

Retrieved on: 
Thursday, February 22, 2024
Nano, Infection, Catheter, Cell wall, Life, Fungal infection, Nanoparticle, Disease, Silver, Mortality, Antibiotics

SALT LAKE CITY, Feb. 22, 2024 /PRNewswire/ -- EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, today announced its antimicrobial medical device platform has demonstrated effectiveness against the world's leading pathogens implicated in healthcare-associated infections (HAIs), which are some of the most common complications of hospital care.

Key Points: 
  • Our nanoparticle technology represents an exciting innovation that could profoundly reduce infections associated with medical devices like catheters without contributing to antibiotic resistance," said Shaun Rothwell, CEO of EVŌQ Nano.
  • By infusing EVŌQ Nano's proprietary nanoparticle, EVQ-218, throughout the polymer itself, medical devices are extrinsically equipped with antimicrobial protection that has proven to be effective against the most prevalent pathogenic microorganisms.
  • EVQ-218 delivers high antimicrobial efficacy without ion emissions.6,7 Its efficacy is rooted in EVQ-218's ability to disrupt bacteria's metabolic processes without triggering antimicrobial resistance.
  • By incorporating antimicrobial protection into the material manufacturing process, EVŌQ Nano's technology enables the next generation of medical devices to more effectively guard against disease.